Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2017; 117(11): 2209-2211
DOI: 10.1160/TH17-07-0474
DOI: 10.1160/TH17-07-0474
Letter to the Editor
Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests
Further Information
Publication History
10 July 2017
07 August 2017
Publication Date:
30 November 2017 (online)
Dear Sirs,
Apixaban is a direct oral anticoagulant (DOAC) that acts on the coagulation cascade by direct factor Xa inhibition. It is currently approved for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in atrial fibrillation patients.[1] Two case reports have described an apixaban overdose thus far,[2] [3] and little is known about apixaban toxicokinetics. We present an apixaban auto-intoxication with corresponding toxicokinetics and coagulation tests.
-
References
- 1 Electronic Medicines Compendium. Eliquis 5 mg film-coated tablets. Bristol-Myers Squibb. Available at: http://www.medicines.org.uk/emc/medicine/27220/SPC/Eliquis+5+mg+film-coated+tablets 2017 . Accessed June 22, 2017
- 2 Barton J, Wong A, Graudins A. Anti-Xa activity in apixaban overdose: a case report. Clin Toxicol (Phila) 2016; 54 (09) 871-873
- 3 Leikin SM, Patel H, Welker KL, Leikin JB. The X factor: lack of bleeding after an acute apixaban overdose. Am J Emerg Med 2017; 35 (05) 801.e5-801.e6
- 4 Siegal DM, Curnutte JT, Connolly SJ. , et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
- 5 Harenberg J, Krämer S, Du S. , et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014; 44 (08) 743-752
- 6 Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost 2014; 12 (11) 1810-1815
- 7 Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110 (02) 283-294